What is Arcturus Therapeutics Holdings?
Arcturus Therapeutics is a clinical-stage biotechnology firm specializing in the development of innovative mRNA-based medicines. The company distinguishes itself through its proprietary RNA technologies and advanced lipid-mediated delivery systems, which are designed to enhance the efficacy and safety of therapeutic payloads. By focusing on both rare diseases and infectious illnesses, Arcturus has established a versatile platform that enables the rapid design and deployment of novel RNA therapies. The company operates at the intersection of molecular biology and pharmaceutical engineering, maintaining a global collaborative network to advance its clinical candidates from the laboratory to human trials. Its commitment to mRNA science positions it as a key player in the next generation of genetic medicine, providing scalable solutions for complex health challenges.
How much funding has Arcturus Therapeutics Holdings raised?
Arcturus Therapeutics Holdings has raised a total of $407.9M across 5 funding rounds:
Debt
$5.9M
Multiple Rounds
$393M
Other Financing Round
$9M
Debt (2014): $5.9M, investors not publicly disclosed
Stock Issuance/Offering (2020): $70M, investors not publicly disclosed
Stock Issuance/Offering (2020): $173M, investors not publicly disclosed
Stock Issuance/Offering (2020): $150M, investors not publicly disclosed
Other Financing Round (2023): $9M backed by Cystic Fibrosis Foundation
Key Investors in Arcturus Therapeutics Holdings
Cystic Fibrosis Foundation
A prominent non-profit organization dedicated to funding research and providing resources to cure cystic fibrosis and improve the quality of life for those affected by the disease.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Arcturus Therapeutics Holdings?
Looking ahead, the recent capital injection is expected to catalyze the advancement of Arcturus Therapeutics' core clinical programs. The firm is likely to prioritize the expansion of its late-stage pipeline, focusing on data readouts that could validate its delivery technology in broader patient populations. Strategic resource allocation will likely center on enhancing manufacturing infrastructure to support potential commercialization efforts. Furthermore, the company is positioned to deepen its collaborative research initiatives, leveraging its mRNA expertise to explore new therapeutic modalities. As the biotechnology sector continues to emphasize precision medicine, Arcturus remains well-capitalized to navigate the regulatory landscape and pursue long-term value creation for its stakeholders through sustained innovation in RNA-based therapeutics.
See full Arcturus Therapeutics Holdings company page
